A sensitive HPLC–MS/MS method for the determination of dolutegravir in human plasma

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet · 2013 · 546 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 514 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacotherapy +16

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Joseph J. Eron, Bonaventura Clotet, J. Durant et al. · The Journal of Infectious Diseases · 2012 · 312 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Jan van Lunzen, Franco Maggiolo, José Ramón Arribas et al. · The Lancet Infectious Diseases · 2011 · 298 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +15

In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor

Melinda J. Reese, Paul Savina, Grant T. Generaux et al. · Drug Metabolism and Disposition · 2012 · 246 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17